Literature DB >> 20800103

Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities.

Juliet N Barker1, Courtney E Byam, Nancy A Kernan, Sinda S Lee, Rebecca M Hawke, Kathleen A Doshi, Deborah S Wells, Glenn Heller, Esperanza B Papadopoulos, Andromachi Scaradavou, James W Young, Marcel R M van den Brink.   

Abstract

Allogeneic transplant access can be severely limited for patients of racial and ethnic minorities without suitable sibling donors. Whether cord blood (CB) transplantation can extend transplant access because of the reduced stringency of required HLA-match is not proven. We prospectively evaluated availability of unrelated donors (URD) and CB according to patient ancestry in 553 patients without suitable sibling donors. URDs had priority if adequate donors were available. Otherwise ≥4/6 HLA-matched CB grafts were chosen utilizing double units to augment graft dose. Patients had highly diverse ancestries including 35% non-Europeans. In 525 patients undergoing combined searches, 10/10 HLA-matched URDs were identified in 53% of those with European ancestry, but only 21% of patients with non-European origins (P < .001). However, the majority of both groups had 5-6/6 CB units. The 269 URD transplant recipients were predominantly European, with non-European patients accounting for only 23%. By contrast, 56% of CB transplant recipients had non-European ancestries (P < .001). Of 26 patients without any suitable stem cell source, 73% had non-European ancestries (P < .001). Their median weight was significantly higher than CB transplant recipients (P <.001), partially accounting for their lack of a CB graft. Availability of CB significantly extends allo-transplant access, especially in non-European patients, and has the greatest potential to provide a suitable stem cell source regardless of race or ethnicity. Minority patients in need of allografts, but without suitable matched sibling donors, should be referred for combined URD and CB searches to optimize transplant access.
Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20800103      PMCID: PMC3685152          DOI: 10.1016/j.bbmt.2010.08.011

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  30 in total

1.  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients.

Authors:  J Kurtzberg; M Laughlin; M L Graham; C Smith; J F Olson; E C Halperin; G Ciocci; C Carrier; C E Stevens; P Rubinstein
Journal:  N Engl J Med       Date:  1996-07-18       Impact factor: 91.245

2.  Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling.

Authors:  E Gluckman; H A Broxmeyer; A D Auerbach; H S Friedman; G W Douglas; A Devergie; H Esperou; D Thierry; G Socie; P Lehn
Journal:  N Engl J Med       Date:  1989-10-26       Impact factor: 91.245

Review 3.  Stored placental blood for unrelated bone marrow reconstitution.

Authors:  P Rubinstein; R E Rosenfield; J W Adamson; C E Stevens
Journal:  Blood       Date:  1993-04-01       Impact factor: 22.113

4.  Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors.

Authors:  P G Beatty; K M Boucher; M Mori; E L Milford
Journal:  Hum Immunol       Date:  2000-08       Impact factor: 2.850

5.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.

Authors:  John E Wagner; Juliet N Barker; Todd E DeFor; K Scott Baker; Bruce R Blazar; Cindy Eide; Anne Goldman; John Kersey; William Krivit; Margaret L MacMillan; Paul J Orchard; Charles Peters; Daniel J Weisdorf; Norma K C Ramsay; Stella M Davies
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

6.  Assessment of optimal size and composition of the U.S. National Registry of hematopoietic stem cell donors.

Authors:  Craig Kollman; Esteban Abella; Robert L Baitty; Patrick G Beatty; Ranajit Chakraborty; Cindy L Christiansen; Robert J Hartzman; Carolyn Katovich Hurley; Edgar Milford; John A Nyman; Thomas J Smith; Galen E Switzer; Randal K Wada; Michelle Setterholm
Journal:  Transplantation       Date:  2004-07-15       Impact factor: 4.939

7.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.

Authors:  Neal Flomenberg; Lee Ann Baxter-Lowe; Dennis Confer; Marcelo Fernandez-Vina; Alexandra Filipovich; Mary Horowitz; Carolyn Hurley; Craig Kollman; Claudio Anasetti; Harriet Noreen; Ann Begovich; William Hildebrand; Effie Petersdorf; Barbara Schmeckpeper; Michelle Setterholm; Elizabeth Trachtenberg; Thomas Williams; Edmond Yunis; Daniel Weisdorf
Journal:  Blood       Date:  2004-06-10       Impact factor: 22.113

8.  Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies.

Authors:  Joanne Kurtzberg; Vinod K Prasad; Shelly L Carter; John E Wagner; Lee Ann Baxter-Lowe; Donna Wall; Neena Kapoor; Eva C Guinan; Stephen A Feig; Elizabeth L Wagner; Nancy A Kernan
Journal:  Blood       Date:  2008-08-21       Impact factor: 22.113

9.  Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow.

Authors:  Juliet N Barker; Timothy P Krepski; Todd E DeFor; Stella M Davies; John E Wagner; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

10.  Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor.

Authors:  P G Beatty; M Mori; E Milford
Journal:  Transplantation       Date:  1995-10-27       Impact factor: 4.939

View more
  53 in total

1.  Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes.

Authors:  Karen K Ballen; John P Klein; Tanya L Pedersen; Deepika Bhatla; Reggie Duerst; Joanne Kurtzberg; Hillard M Lazarus; Charles F LeMaistre; Phillip McCarthy; Paulette Mehta; Jeanne Palmer; Michelle Setterholm; John R Wingard; Steven Joffe; Susan K Parsons; Galen E Switzer; Stephanie J Lee; J Douglas Rizzo; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2011-11-04       Impact factor: 5.742

2.  Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources.

Authors:  Karen K Ballen; Steven Joffe; Ruta Brazauskas; Zhiwei Wang; Mahmoud D Aljurf; Görgün Akpek; Christopher Dandoy; Haydar A Frangoul; César O Freytes; Nandita Khera; Hillard M Lazarus; Charles F LeMaistre; Paulette Mehta; Susan K Parsons; David Szwajcer; Celalettin Ustun; William A Wood; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-23       Impact factor: 5.742

3.  Cord blood unit factors influencing transplant outcomes from the Asian multiethnic Singapore Cord Blood Bank.

Authors:  S-Y Ong; C Phipps; P Chu; A Prasath; A Y L Ho; S J Sobak; W Hwang
Journal:  Bone Marrow Transplant       Date:  2015-06-08       Impact factor: 5.483

4.  Going home for the holidays? Take a shortcut!

Authors:  L Metheny; M de Lima
Journal:  Bone Marrow Transplant       Date:  2017-01-23       Impact factor: 5.483

Review 5.  Cord blood transplantation: rewind to fast forward.

Authors:  A Dahlberg; F Milano
Journal:  Bone Marrow Transplant       Date:  2016-12-19       Impact factor: 5.483

6.  US public cord blood banking practices: recruitment, donation, and the timing of consent.

Authors:  Sherri M Broder; Roselle S Ponsaran; Aaron J Goldenberg
Journal:  Transfusion       Date:  2012-07-15       Impact factor: 3.157

7.  Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.

Authors:  D M Ponce; A Gonzales; M Lubin; H Castro-Malaspina; S Giralt; J D Goldberg; A M Hanash; A Jakubowski; R Jenq; E B Papadopoulos; M A Perales; M R M van den Brink; J W Young; F Boulad; R J O'Reilly; S Prockop; T N Small; A Scaradavou; N A Kernan; C E Stevens; J N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-14       Impact factor: 5.742

8.  Reduction in Mortality after Umbilical Cord Blood Transplantation in Children Over a 20-Year Period (1995-2014).

Authors:  Lisa P Spees; Paul L Martin; Joanne Kurtzberg; Andre Stokhuyzen; Lauren McGill; Vinod K Prasad; Timothy A Driscoll; Suhag H Parikh; Kristin M Page; Richard Vinesett; Christopher Severyn; Anthony D Sung; Alan D Proia; Kirsten Jenkins; Mehreen Arshad; William J Steinbach; Patrick C Seed; Matthew S Kelly
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-24       Impact factor: 5.742

9.  The increase of the global donor inventory is of limited benefit to patients of non-Northwestern European descent.

Authors:  Suzanna M van Walraven; Anneke Brand; Jack N A Bakker; Martin B A Heemskerk; Suzan Nillesen; Marc B Bierings; Laura B Bungener; Bouke G Hepkema; Arjan Lankester; Arnold van der Meer; Kees Sintnicolaas; Judith A E Somers; Eric Spierings; Marcel G J Tilanus; Christien E M Voorter; Jan J Cornelissen; Machteld Oudshoorn
Journal:  Haematologica       Date:  2016-08-25       Impact factor: 9.941

10.  Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.

Authors:  Theresa Hahn; Philip L McCarthy; Anna Hassebroek; Christopher Bredeson; James L Gajewski; Gregory A Hale; Luis M Isola; Hillard M Lazarus; Stephanie J Lee; Charles F Lemaistre; Fausto Loberiza; Richard T Maziarz; J Douglas Rizzo; Steven Joffe; Susan Parsons; Navneet S Majhail
Journal:  J Clin Oncol       Date:  2013-05-28       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.